Amgen Inc. — 2021 Form 10-K Summary
Business context and reporting period
Amgen is a global biotechnology company operating in one segment, human therapeutics. This annual report covers the fiscal year ended December 31, 2021; the figures below compare full-year 2021 with 2020, not fourth-quarter results.
Key financial metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Total revenues | $25.979 billion | $25.424 billion | +2% |
| Product sales | $24.297 billion | $24.240 billion | Flat |
| Operating income | $7.639 billion | $9.139 billion | -16% |
| Net income | $5.893 billion | $7.264 billion | -19% |
| Diluted EPS | $10.28 | $12.31 | -16% |
| Operating cash flow | $9.261 billion | $10.497 billion | Down |
Operating margin was approximately 29.4% of revenue, compared with 35.9% in 2020; net margin was approximately 22.7%, compared with 28.6%. Operating expenses rose 13% to $18.340 billion, including $1.505 billion of acquired in-process R&D expense, principally for Five Prime’s bemarituzumab program. R&D expense was $4.819 billion, up 15%. The effective tax rate was 12.1%, versus 10.7%.
At year-end, cash, cash equivalents and marketable securities totaled $8.037 billion, down from $10.647 billion. Total debt carrying value was $33.309 billion, including $33.222 billion of long-term debt and $87 million current. Current assets were $19.385 billion and current liabilities $12.184 billion. Capital expenditures were $880 million; management estimated 2022 capital-project spending of approximately $950 million.
Material changes versus 2020
- U.S. product sales decreased 4% to $17.286 billion, while rest-of-world sales increased 12% to $7.011 billion. Management attributed the overall flat product-sales result to volume growth offset by lower net selling prices.
- Sales increased for Prolia (+18%), Repatha (+26%), Nplate (+21%) and XGEVA (+6%). Neulasta fell 24%, ENBREL 11% and Aranesp 6%, amid pricing pressure and competition, including biosimilars.
- Operating income and earnings declined as higher operating expenses, including acquisition and collaboration-related R&D charges, more than offset revenue growth. Other revenues rose 42% to $1.682 billion, primarily reflecting COVID-19 antibody material sales under a manufacturing collaboration.
- Cash from operations declined by $1.236 billion; management cited the prior-year monetization of interest-rate swaps and timing of sales-incentive and discount payments. Investing cash flow was positive $733 million, including net marketable-securities inflows and $2.529 billion of acquisition spending. Financing cash outflow was $8.271 billion.
Outlook, commentary, risks and unusual items
- Management expected portfolio-level net selling prices to continue declining in 2022 due to competition. It also anticipated variable demand in the first half of 2022 amid Omicron-related effects and said the pandemic’s cumulative reduction in diagnoses could continue to constrain new treatment starts.
- Amgen reported no COVID-related medicine supply disruptions or shortages to date, but identified potential risks to clinical trials, patient access, demand, supply chains and operations.
- Major business developments included the Five Prime acquisition for approximately $1.6 billion net of acquired cash, Teneobio’s acquisition for $994 million upfront plus potential milestone payments, and a $400 million upfront payment under the KKC collaboration. Teneobio’s potential contingent payments are up to $1.6 billion; KKC payments may reach $850 million under specified milestones.
- The company repurchased 21.7 million shares for approximately $5.0 billion and paid $4.0 billion in dividends during 2021. The board declared a first-quarter 2022 dividend of $1.94 per share. Amgen said it expected available funds, operating cash flow and financing access to meet anticipated needs.
- Amgen is contesting IRS notices for 2010–2012 that could result in approximately $3.6 billion of additional federal tax plus interest, subject to a potential reduction of up to approximately $900 million for previously accrued repatriation tax. Gross unrecognized tax benefits were $3.546 billion; accrued interest and penalties on these benefits were $881 million. The company said final resolution was not likely within 12 months.
- Other key risks include intensifying biosimilar and generic competition, payer pricing and reimbursement pressure, reliance on three wholesalers (82% of worldwide gross revenues in 2021), manufacturing concentration in Puerto Rico and Thousand Oaks, litigation and patent challenges, and clinical-development and regulatory uncertainty. Amgen reported effective disclosure controls and internal control over financial reporting; the auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Review the complete financial statements and notes for debt maturities, liquidity, cash-flow drivers and acquisition-related charges.
- Track the IRS transfer-pricing dispute, tax accruals and potential exposure, as well as material litigation and patent outcomes.
- Assess whether growth in newer products and ROW sales can offset U.S. pricing pressure and declining sales of products facing biosimilar competition.
- Monitor 2022 pricing, demand and patient-access trends, including continued pandemic effects and payer decisions.
- Verify progress, costs and supply impact from manufacturing expansion and the company’s contingent milestone obligations.